Emerging NASDAQ company may revolutionize the future of immunotherapy

A wonder drug that may revolutionize the fight against Alzheimer's!  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ [Unsubscribe]( [This tiny biotech firm aims to bring to market a unique drug candidate that could significantly help millions of people!]( One underfollowed NASDAQ company is developing transformational formulation technologies, enabling a switch from traditional routes to alternative routes of immunotherapy to facilitate local sites of action. This includes nasal, oral, and inhalation administrations to target neurodegenerative diseases. Why is this important? The company believes that if it succeeds in these alternative routes of immunotherapies, it has the potential to revolutionize the way immunotherapies are administered! There are several reasons to have this tiny biotech firm on your radar. The company’s lead asset is Intranasal Foralumab, which has multiple administration routes of a proven systemic anti-inflammatory and is patent protected until 2040. The company’s lead program is in non-active Secondary Progressive Multiple Sclerosis and it is IND cleared and “may proceed” to study foralumab in Alzheimer’s Disease! Foralumab is gaining recognition across the scientific community with features in medical media that include Pharmacy Times. It was also recently highlighted positively in a Forbes article. The company has also submitted an FDA request to obtain an Orphan Drug Designation for intranasal foralumab for the treatment of non-active secondary progressive Multiple Sclerosis (na-SPMS). This request would make foralumab the first therapy for na-SPMS to receive Orphan Drug Designation! [Learn how an experienced scientific advisory board and management team that has brought multiple drugs to market could turn TLSA into a pioneer in immunotherapy treatment.]( --------------------------------------------------------------- This message is a PAID ADVERTISEMENT for Tiziana Life Sciences Ltd (NASDAQ: TLSA) from Interactive Offers. StockEarnings, Inc receives a fixed fee for each subscriber that clicks on a link in this email, totaling up to $2450. Other than the compensation received for this advertisement sent to subscribers, StockEarnings and its principals are not affiliated with either Tiziana Life Sciences Ltd (NASDAQ: TLSA) or Interactive Offers. StockEarnings and its principals do not own any of the stocks mentioned in this email or in the article that this email links to. Neither StockEarnings nor its principals are FINRA-registered broker-dealers or investment advisers. The content of this email should not be taken as advice, an endorsement, or a recommendation from StockEarnings to buy or sell any security. StockEarnings has not evaluated the accuracy of any claims made in this advertisement. StockEarnings recommends that investors do their own independent research and consult with a qualified investment professional before buying or selling any security. Investing is inherently risky. Past-performance is not indicative of future results. Please see the disclaimer regarding Tiziana Life Sciences Ltd (NASDAQ: TLSA) on Small Caps Daily website for additional information about the relationship between Interactive Offers and Tiziana Life Sciences Ltd (NASDAQ: TLSA). Your privacy is very important to us, if you wish to be excluded from future notices, do not reply to this message. Instead, please click [Unsubscribe](. StockEarnings, Inc 33 SE 4th St, Suite 100, Boca Raton, FL 33432 USA W: 877.6.STOCKS StockEarnings.com [Today's Bonus Content: $200 Trillion "AI Phase 2" Moments Away?](